文献速递药物相互作用药物不良反应与药物警戒肝肾功能剂量调整

他汀与秋水仙碱药物相互作用的系统综述:患者特征、病因及临床管理策略

A systematic review of the drug-drug interaction between statins and colchicine: Patient characteristics, etiologies, and clinical management strategies.
PubMed 文献 · Pharmacotherapy · 2022-02-25

Colchicine and statins are frequently co-prescribed for prevention and treatment of cardiovascular diseases, auto-inflammatory diseases, and gout.…

要点

  • 他汀与秋水仙碱联用可致肌病、横纹肌溶解等严重不良事件,需警惕。
  • 合并肾脏疾病、肝硬化、秋水仙碱日剂量≥1.2 mg及合用CYP3A4/P-gp相互作用药物为肌病风险因素。
  • 临床应针对他汀相关肌肉症状采取风险缓解策略,如调整剂量或换药。

核心结论

  • 他汀与秋水仙碱联用存在临床显著相互作用,可能导致肌病、横纹肌溶解等严重不良事件。
  • 临床医生应认识到该相互作用风险,并采取风险缓解策略管理他汀相关肌肉症状。

主要发现

  • 超过70%的患者在辛伐他汀或阿托伐他汀治疗时发生不良事件,80%的研究报告使用中等至高强度他汀。
  • 秋水仙碱日剂量范围为0.5至1.5 mg。

临床怎么用

  • 临床医生应警惕他汀-秋水仙碱联用可能导致的患者伤害,对出现他汀相关肌肉症状者应评估并采取风险缓解策略。
  • 对合并肾脏疾病、肝硬化、使用秋水仙碱日剂量≥1.2 mg或合用CYP3A4/P-gp相互作用药物的患者,应加强监测。
  • 未来需研究验证与该相互作用并发症强烈相关的临床风险因素。

局限性

  • 证据主要来自病例报告/系列,回顾性观察性研究仅2项、病例对照研究仅1项,样本量有限。
  • 秋水仙碱剂量范围较宽,不良事件与剂量关系需进一步明确。
  • 需未来研究验证临床相关风险因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Colchicine and statins are frequently co-prescribed for prevention and treatment of cardiovascular diseases, auto-inflammatory diseases, and gout. Both are substrates and inhibitors of the cytochrome P-450 (CYP) 3A4 isozyme and P-glycoprotein so that taken together, they represent a clinically significant interaction. Data suggest the interaction may be associated with potentially life-threatening myopathies and rhabdomyolysis. The purposes of this systematic review (SR) were to gather and appraise evidence surrounding the statin-colchicine drug interaction and discuss related risk-mitigation strategies. An electronic literature search was performed. Twenty-one articles met the protocol to be included in the qualitative analysis: 18 case reports/series, 2 retrospective observational cohort studies, and 1 retrospective case-control study. Thirty-eight patients developed an adverse drug event (ADE) receiving statin-colchicine combination therapy; 25 (66%) patients developed myopathy; 10 (26%) patients developed rhabdomyolysis, and three (8%) patients developed neuromyopathy. Over 70% of patients developed ADEs on simvastatin or atorvastatin, and 80% of studies reported moderate-to-high intensity statins. Colchicine dosing varied but ranged between 0.5 to 1.5 mg daily. Sixty-two percent of patients in the case reports/series had comorbid renal disease. Seven studies (33% of all included studies) reported patients taking concomitant interacting medications at the CYP3A4 and/or P-glycoprotein efflux pump. Seventeen studies (81% of all included studies) reported ADEs leading to hospitalization. A multivariate analysis from one case-control study identified risk factors prognosticating myopathy ADEs in patients taking statin-colchicine therapy: comorbid renal disease and/or cirrhosis, colchicine doses 1.2 mg daily or greater, and concomitant interacting medications. Clinicians must be cognizant that the statin-colchicine drug interaction may lead to patient harm and thus should employ risk-mitigation strategies for statin-associated muscle symptoms. Future studies are warranted to validate clinically relevant risk factors that are strongly associated with the complications owing to the statin-colchicine drug interaction.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Schwier NC, Cornelio CK, Boylan PM, et al. A systematic review of the drug-drug interaction between statins and colchicine: Patient characteristics, etiologies, and clinical management strategies. Pharmacotherapy. 2022. PMID: 35175631. doi:10.1002/phar.2674

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。